FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313643511> ?p ?o ?g. }

• W4313643511 endingPage "1152" @default.
• W4313643511 startingPage "1142" @default.
• W4313643511 abstract "Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13.1720 healthy infants were randomized 1:1 to receive a 4-dose regimen of V114 or PCV13 concomitantly with other routine pediatric vaccines. Safety was evaluated after each dose as proportion of participants with adverse events (AEs). Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured at 1-month post-dose 3 (PD3), pre-dose 4, and 1-month post-dose 4 (PD4). IgG response rates, geometric mean concentrations (GMCs), and opsonophagocytic activity (OPA) were compared between vaccination groups.The proportion, maximum intensity, and duration of injection-site, systemic, and serious AEs were generally comparable between V114 and PCV13 groups. In comparison to PCV13, V114 met non-inferiority criteria for all 15 serotypes based on IgG response rates at PD3. V114 met non-inferiority criteria by IgG GMCs for all serotypes at PD3 and PD4, except for serotype 6A at PD3. V114-induced antibodies had bactericidal activity as assessed by OPA. Further, V114 met superiority criteria for shared serotype 3 and unique serotypes 22F and 33F compared to PCV13 by serotype-specific IgG GMCs at both PD3 and PD4. Immunogenicity of concomitantly administered routine pediatric vaccines was comparable in V114 and PCV13 groups.In healthy infants, V114 displays acceptable safety and tolerability profiles and generates comparable immune responses to PCV13. V114 also met superiority criteria for serotypes 3, 22F, and 33F. These results support use of V114 for prevention of PD as part of routine infant vaccination schedules.ClinicalTrials.gov: NCT03893448; EudraCT: 2018-004109-21." @default.
• W4313643511 created "2023-01-07" @default.
• W4313643511 creator A5000268660 @default.
• W4313643511 creator A5004928964 @default.
• W4313643511 creator A5006526775 @default.
• W4313643511 creator A5013975567 @default.
• W4313643511 creator A5020967266 @default.
• W4313643511 creator A5030667842 @default.
• W4313643511 creator A5037368215 @default.
• W4313643511 creator A5039222466 @default.
• W4313643511 creator A5045742048 @default.
• W4313643511 creator A5047774558 @default.
• W4313643511 creator A5052872357 @default.
• W4313643511 creator A5053118577 @default.
• W4313643511 creator A5059440499 @default.
• W4313643511 creator A5064296683 @default.
• W4313643511 creator A5077502906 @default.
• W4313643511 creator A5081029814 @default.
• W4313643511 creator A5086250528 @default.
• W4313643511 creator A5089484814 @default.
• W4313643511 date "2023-01-01" @default.
• W4313643511 modified "2023-09-25" @default.
• W4313643511 title "A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)" @default.
• W4313643511 cites W1963985157 @default.
• W4313643511 cites W2022570321 @default.
• W4313643511 cites W2023116174 @default.
• W4313643511 cites W2023690749 @default.
• W4313643511 cites W2025200855 @default.
• W4313643511 cites W2041643249 @default.
• W4313643511 cites W2056360579 @default.
• W4313643511 cites W2056667158 @default.
• W4313643511 cites W2068751923 @default.
• W4313643511 cites W2094689350 @default.
• W4313643511 cites W2110447600 @default.
• W4313643511 cites W2110584975 @default.
• W4313643511 cites W2111717771 @default.
• W4313643511 cites W2122633654 @default.
• W4313643511 cites W2128173146 @default.
• W4313643511 cites W2133150648 @default.
• W4313643511 cites W2135761651 @default.
• W4313643511 cites W2140370976 @default.
• W4313643511 cites W2150562212 @default.
• W4313643511 cites W2295618196 @default.
• W4313643511 cites W2397263409 @default.
• W4313643511 cites W2588291917 @default.
• W4313643511 cites W2613751645 @default.
• W4313643511 cites W2637555307 @default.
• W4313643511 cites W2808668519 @default.
• W4313643511 cites W2903878519 @default.
• W4313643511 cites W2911852415 @default.
• W4313643511 cites W2986087392 @default.
• W4313643511 cites W3006591212 @default.
• W4313643511 cites W3026175339 @default.
• W4313643511 cites W3040949579 @default.
• W4313643511 cites W3043620968 @default.
• W4313643511 cites W3088047542 @default.
• W4313643511 cites W3150530058 @default.
• W4313643511 cites W3184745312 @default.
• W4313643511 cites W3197128884 @default.
• W4313643511 cites W4239909494 @default.
• W4313643511 doi "https://doi.org/10.1016/j.vaccine.2022.12.054" @default.
• W4313643511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36621410" @default.
• W4313643511 hasPublicationYear "2023" @default.
• W4313643511 type Work @default.
• W4313643511 citedByCount "7" @default.
• W4313643511 countsByYear W43136435112023 @default.
• W4313643511 crossrefType "journal-article" @default.
• W4313643511 hasAuthorship W4313643511A5000268660 @default.
• W4313643511 hasAuthorship W4313643511A5004928964 @default.
• W4313643511 hasAuthorship W4313643511A5006526775 @default.
• W4313643511 hasAuthorship W4313643511A5013975567 @default.
• W4313643511 hasAuthorship W4313643511A5020967266 @default.
• W4313643511 hasAuthorship W4313643511A5030667842 @default.
• W4313643511 hasAuthorship W4313643511A5037368215 @default.
• W4313643511 hasAuthorship W4313643511A5039222466 @default.
• W4313643511 hasAuthorship W4313643511A5045742048 @default.
• W4313643511 hasAuthorship W4313643511A5047774558 @default.
• W4313643511 hasAuthorship W4313643511A5052872357 @default.
• W4313643511 hasAuthorship W4313643511A5053118577 @default.
• W4313643511 hasAuthorship W4313643511A5059440499 @default.
• W4313643511 hasAuthorship W4313643511A5064296683 @default.
• W4313643511 hasAuthorship W4313643511A5077502906 @default.
• W4313643511 hasAuthorship W4313643511A5081029814 @default.
• W4313643511 hasAuthorship W4313643511A5086250528 @default.
• W4313643511 hasAuthorship W4313643511A5089484814 @default.
• W4313643511 hasBestOaLocation W43136435111 @default.
• W4313643511 hasConcept C10389963 @default.
• W4313643511 hasConcept C126322002 @default.
• W4313643511 hasConcept C159047783 @default.
• W4313643511 hasConcept C159654299 @default.
• W4313643511 hasConcept C197934379 @default.
• W4313643511 hasConcept C203014093 @default.
• W4313643511 hasConcept C22070199 @default.
• W4313643511 hasConcept C2778375690 @default.
• W4313643511 hasConcept C2778866548 @default.
• W4313643511 hasConcept C2779301066 @default.
• W4313643511 hasConcept C2779583294 @default.
• W4313643511 hasConcept C2780868878 @default.

• next